Phase II Study to Evaluate the Cardiac Safety of 2 Doses of CHF5993 Both Combined With CHF1535 BID Versus CHF1535 BID in Patients With Moderate to Severe COPD

Phase 2

Completed

• Conditions: Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)
• Interventions: Drug: CHF1535 daily dose; Drug: CHF1535 + CHF5992 dose2 BID; Drug: CHF1535 + CHF5992 dose 1 BID

• Registration Number: NCT01584505
• Lead Sponsor: Chiesi Farmaceutici S.p.A.

Brief Summary

Cardiac Safety Study

Detailed Description

The purpose of this study is to demonstrate equivalence between CHF1535 plus CHF5992 (two different dosages) over CHF1535 alone in change from baseline in average 24-hour heart rate, as primary end point, and other ECG parameters.

Study Timeline

• Study Start: 2012-04
• Study First Submitted: 2012-04-23
• Study First Submitted QC: 2012-04-24
• Study First Posted: 2012-04-25
• Primary Completion: 2012-09
• Study Completion: 2013-01
• Status Verified: 2021-10
• Last Update Submitted: 2021-10-28
• Last Update Posted: 2021-10-29

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 191

Inclusion Criteria

1. Male and female adults ≥ 40years and ≤ 80years old

2. Male subjects: they and/or their partner must be willing to use an approved method of contraception 1) from the time of dose administration and until 30 days after the last dose of study. Subjects must not donate sperm for 30 days after the last dose of study drug

3. Written informed consent obtained by the patient prior to any study related procedures

4. Outpatient with diagnosis of COPD (defined in GOLD guidelines, up to date 2010) at least in the 6 months before the screening visit, including:

   • Smoking history of at least 10 pack years defined as [(number of cigarettes smoked per day) x (number of years of smoking)]/20; both current and ex smokers are eligible. For patients who are in smoking cessation therapy this must be completed at least 1 week before study enrollment
   • Regular use of bronchodilators (e.g. β2-agonist or/and anticholinergics) in the previous 2 months at Visit 0
   • Post-bronchodilator FEV1 ≥ 30% and ≤ 60% of the predicted normal value
   • Post-bronchodilator FEV1/FVC ≤ 0.70

Exclusion Criteria

1. Pregnant or lactating women or all women physiologically capable of becoming pregnant UNLESS they meet the following definition of postmenopausal: 12 months of natural (spontaneous) amenorrhea or 6 months of spontaneous amenorrhea with already documented serum FSH level > 40mlU/mL or are using one of the following acceptable methods of contraception

   • Surgical sterilization (e.g. bilateral tubal ligation, hysterectomy)
   • Hormonal contraception (implantable, patch, oral)
   • Double-barrier methods (any double combination of: IUD, male or female condom with spermicidal gel, diaphragm, sponge, cervical cap) Reliable contraception should be maintained throughout the study and for 30 days after study drug discontinuation

2. Current diagnosis of asthma or other respiratory disorders (other than COPD) which may interfere with data interpretation according to the investigator's opinion

3. Hospitalization due to COPD exacerbation in the three months prior to screening and during run-in period or COPD exacerbation requiring systemic steroids and or antibiotics in the 6 weeks prior to screening and during run-in period. COPD exacerbation will be defined according to the following criteria: a sustained worsening of the patient condition (dyspnoea, cough and/or sputum production/purulence), from the stable state and beyond normal day-to-day variations, that is acute in onset and necessitates a change in regular medication that includes prescription of oral corticosteroids and/or antibiotics, or need for hospitalization.

4. Patient with COPD who requires regular long term use of oxygen therapy

5. Patient who requires chronic mechanical ventilation for COPD

6. Patient treated regularly with oral or parenteral corticosteroids for their COPD

7. Change of COPD regular medication in the 4 weeks prior to enrollment

8. Unstable CV diseases

9. Known abnormality of any cardiac valve

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
CHF1535 HFA pMDI + Placebo	CHF1535 daily dose	CHF1535 HFA pMDI BID plus placebo BID
CHF5993 HFA pMDI dose 2, BID	CHF1535 + CHF5992 dose2 BID	CHF5993 HFA pMDI dose 2, BID
CHF5993 HFA pMDI dose 1, BID	CHF1535 + CHF5992 dose 1 BID	CHF5993 HFA pMDI dose 1, BID

Primary Outcome Measures

Name	Time	Method
Change from baseline in average 24-hour heart rate at Final visit	Day 14 of study treatment	To assess the effect on change from baseline in average 24h Heart Rate at Day 14 of study treatment

Secondary Outcome Measures

Name	Time	Method
Heart Rate and ECG parameters variation	Day 1 and Day 14 of Study Treatment	Pre and post-dose

Trial Locations

Locations (6)

Hospital "Lozenets"; 🇧🇬 Sofia, Bulgaria

Fővárosi Önkormányzat Szent János Kórháza és Észak-budai Egyesített Kórházai Tüdőgondozó Szakrendelő; 🇭🇺 Budapest, Hungary

Medicines Evaluation Unit, Langley Building; 🇬🇧 Manchester, United Kingdom

Praxis Dr. Kampschulte; 🇩🇪 Berlin, Germany

ISPL Centrum Medyczne Robert M. Mróz; 🇵🇱 Białystok, Poland

State Budgetary Healthcare Institution of Moscow city; 🇷🇺 Moscow, Russian Federation